Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Humanized Antibody Library Screening and Transferrin Receptor Development

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract involves the customized screening of a humanized antibody library to develop a functional transferrin receptor, encompassing molecular design, in vitro selection, and optimization of binding affinity and specificity. The work requires advanced techniques in antibody engineering to identify and refine candidates capable of high-affinity, selective interaction with the transferrin receptor, with the goal of producing a therapeutically viable candidate. The scope includes iterative cycles of library screening, functional characterization, and structural optimization to enhance target binding while minimizing off-target interactions, ensuring the final product meets stringent performance benchmarks. This subcontract is issued under the NAICS code 541714 for research and development in the biological sciences and is associated with the National Institutes of Health through the Department of Health and Human Services. The place of performance is in Bethesda, Maryland, with a deadline for proposals set for July 31, 2026. The contract is expected to support biomedical innovation targeting receptor-mediated delivery systems and requires expertise in molecular biology, high-throughput screening, and protein engineering. No specific set-aside provisions are indicated, and the work is open to qualified subcontractors capable of delivering scalable, data-driven antibody development solutions within the defined timeline.

General Info

Custom antibody screening for transferrin receptor binding via molecular engineering in Bethesda, Maryland, by July 31, 2026.

Agency

Department Of Health And Human Services → National Institutes Of Health OlaoView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health Olao
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Customized screening of a humanized antibody library to develop a functional transferrin receptor, including molecular design, in vitro selection, and optimization of binding affinity and specificity.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Develop and Validate Transferrin ReceptorThe National Institutes of Health, under the Department of Health and Human Services, has issued a presolicitation notice for the development and validation of a transferrin receptor, identified by solicitation number 75N98026Q00866. This opportunity is open for responses until July 31, 2026, and was posted on July 24, 2026, with no set-aside provisions applied, making it open to all eligible entities. The work will be performed in Bethesda, Maryland, and falls under the NAICS code 541714, which corresponds to research and development in the physical, engineering, and life sciences. The primary point of contact for inquiries is Towanda Daniels, reachable via email at danielt@mail.nih.gov. Interested parties are directed to the official SAM.gov workspace link for further details and submission guidelines. The contract aims to support advanced scientific research focused on the transferrin receptor, likely to advance biomedical applications or therapeutic technologies. All proposals must adhere to the requirements outlined in the notice of intent, and submissions should be prepared with consideration for the technical scope, timeline, and performance standards expected by the NIH Office of Laboratory Animal Welfare. The contract is structured to enable innovation in molecular biology or drug delivery systems involving receptor targeting, with performance expected within the confines of federal research protocols and compliance standards.
National Institutes Of Health Olao

POSTED

about 19 hours ago

DEADLINE

in 6 days
View Details
NAICS: 541714
New
Federal
Procurement of lateral flow (LFA) strips for the rapid HIV nucleic acid diagnostic testThe Centers for Disease Control and Prevention is soliciting bids for the procurement of 4,000 lateral flow strips intended for use in a rapid HIV nucleic acid diagnostic test under a firm-fixed-price contract, issued as a Request for Quote in accordance with FAR Subpart 12 for commercial items. The solicitation number is 75D30126Q79099, with a performance period of August 1, 2026, to December 31, 2026, and an option to extend services for up to six additional months. Proposals must be submitted electronically to Eugene Gutierrez at zvm0@cdc.gov no later than 3:00 P.M. Eastern Standard Time on Friday, July 24, 2026, with no telephonic or paper submissions accepted. The place of performance is the CDC facility at 1600 Clifton Road, Building 17, Atlanta, GA 30329-4018. Offerors must be registered in the System for Award Management at the time of submission and are required to comply with all applicable FAR clauses, including 52.212-1 and 52.212-4, along with deviations such as those addressing trafficking in persons, contractor employee whistleblower rights, sustainable products and services, Buy American Act alternatives for Israeli and Korean end products, and prohibitions on unauthorized information sharing. Technical evaluation is the predominant factor in award, emphasizing experience with biomedical devices, FDA approval processes, and prior work with lateral flow technology, with price considered secondary. The contractor must deliver 200 prototype strips and 4,000 final units meeting stringent performance standards: ≤0.5% false positive rate and ≤1% false negative rate using CDC’s LAMP reaction, and must ensure full compatibility with CDC’s mass production protocols. All deliverables must conform to Section 508 accessibility requirements, including WCAG 2.0 Level AA, and vendors must provide a Voluntary Product Accessibility Template or HHS conformance checklist. The contract imposes strict security and confidentiality obligations, including mandatory non-disclosure agreements for all employees accessing sensitive information, identification protocols to distinguish contractor personnel from government staff, and prohibitions against retaining or disseminating federal records or Privacy Act data. Subcontractors must be bound by the same requirements, and all payments must be processed via the Treasury’s Invoice Processing Platform using an ACH Vendor Enrollment
CDC Office Of Acquisition Services

POSTED

about 19 hours ago

DEADLINE

in 5 days
View Details
NAICS: 541714
New
Federal
Battlefield Pain Management – AnalgesicThis solicitation under the prototype Other Transaction Authority (10 U.S.C. 4022) seeks the development of a single-use analgesic product for acute moderate to severe battlefield pain, with the ultimate goal of obtaining FDA approval. The product must be a combination drug-device system—such as a nasal spray or autoinjector—that is rapid to administer, compact for individual carry, and stable under extreme environmental conditions, capable of withstanding temperature excursions between -25°C and 45°C without refrigeration and maintaining a 2-3 year shelf life at controlled room temperature. It must comply with USP <659> packaging and storage standards, adhere to 21 CFR Part 820 quality system regulations for labeling and control, and meet strict physiological limits including no more than a 20% reduction in baseline blood pressure, heart rate, or blood clotting ability. The product must be classified as a DEA Schedule II or higher controlled substance and must not require special handling for humidity, pressure, or temperature, verified through MIL-STD-810 testing. The effort spans an estimated eight-year period, divided into three sequential objectives: three years for Chemistry, Manufacturing, and Controls (CMC) and stability studies; two years for non-clinical enabling studies; and three years for clinical trials and human factors testing, including potential Emergency Use Authorization (EUA) submission. Deliverables include detailed regulatory documentation, study strategies, interim and final reports, regulatory meeting minutes, protocol approvals from IACUC and ORRC, and full compliance with Controlled Unclassified Information (CUI) marking and data handling protocols. The contract does not fall under FAR or DFARS, but incorporates selected clauses for electronic payment submission, government property management, and termination for convenience. Proposals must be submitted in three volumes—Technical, Management, and Administrative and Cost—with the technical volume limited to 20 pages plus an unlimited attachment for the Statement of Work. A key eligibility requirement is a pass/fail gate: the proposal must demonstrate participation of at least one nontraditional defense contractor or nonprofit research institute, or that all significant participants are small businesses or nontraditional contractors, or that at least one-third of the total project cost is funded by non-federal sources. The proposal deadline has been extended to August 14, 2026, with all submissions required via email in searchable PDF format, compatible with Microsoft Office and Adobe Acrobat, and free of malware, passwords, or hyperlinks.
Defense Health Agency

POSTED

2 days ago

DEADLINE

in 21 days
View Details
NAICS: 541714
New
Federal
Development of Light-Responsive Artificial Cells using Plant-Based Photoreceptor SystemsThe United States Army Corps of Engineers Engineer Research and Development Center Construction Engineering Research Laboratory is seeking to develop light-responsive artificial cells by integrating plant-derived UVR8 photoreceptor systems into synthetic biology platforms, using high-throughput protein engineering and AI-assisted structural refinement to create programmable, pseudo-living systems activated by environmental light stimuli. The project aims to advance foundational science in synthetic biology by leveraging Bioconscientia, LLC’s uniquely specialized expertise in UVR8 photoreceptor technology, which enables precise sensing of UV-B light in a manner unmatched by other entities. Due to the highly specialized nature of the required research and Bioconscientia’s irreplaceable knowledge of existing experimental data and technical pathways, the government intends to award a sole-source contract to this vendor under RFO FAR 12.102(a), with an anticipated award date of September 30, 2026. This presolicitation notice, issued under FAR Part 5.101(a) with solicitation number W9132T26QA015 and NAICS code 541714, does not constitute a formal request for proposals or a competitive procurement, nor is it a set-aside. Interested parties may submit capability statements to CERL-CT-QUOTES@USACE.ARMY.MIL by July 31, 2026, to be reviewed for potential technical equivalency, but submission does not guarantee a change to the government’s acquisition strategy. The government retains full discretion to proceed with sole-source award regardless of responses received. All work will be performed in Champaign, Illinois, and the primary point of contact for submissions is Lurline L. Simmons, with Andrea J. Thomas serving as the contracting officer. No telephone inquiries will be accepted.
W2R2 Construction Engrg Labor

POSTED

3 days ago

DEADLINE

in 6 days
View Details
NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is soliciting collaborative participation through a continuous, open Participant Basic Agreement (PBA) under the HEALER portfolio to advance next-generation, threat-agnostic host-directed therapeutics designed to enhance physiological resilience against CBRN threats. This initiative targets five critical biological systems—neurological protection, respiratory stabilization, immune modulation, hematologic and vascular function, and cellular stress and repair pathways—with the goal of developing dual-use medical countermeasures that serve both military and civilian critical care needs. The program invites two categories of collaborators: therapeutic developers with candidates that modulate host response mechanisms and drug development support providers including CROs and CDMOs with capabilities in preclinical testing, clinical trial execution, cGMP manufacturing, regulatory strategy, and advanced modeling. Submission requires a white paper of no more than five pages excluding a cover page, detailing product mechanism of action, efficacy data from validated animal models, regulatory status such as IND experience and clinical trial history, manufacturing capacity and scale-up plans, and company profile for therapeutic developers, or core capabilities and infrastructure for service providers. All participants must express willingness to collaborate with other PBA holders to foster an integrated development ecosystem. The solicitation, issued under statutory authority of 10 U.S.C. §§4021–4023, operates outside the Competition in Contracting Act and does not follow traditional procurement or evaluation frameworks, eliminating standard contract clauses, formal evaluation factors, pricing structures, or submission deadlines. Instead, awards are made at the government’s discretion through a non-traditional acquisition mechanism designed to accelerate innovation. Technical and administrative inquiries are directed to Hunter Robinson and Alexander Mayatte at the U.S. Army’s Aberdeen Proving Ground, Maryland office. Participation prerequisites include current registration in the System for Award Management (SAM), compliance with FDA regulatory pathways, and adherence to cGMP standards for manufacturing. While no specific delivery dates, FOB terms, inspection criteria, or cost estimates are defined, performance is expected to align with the mission of CPE CBRND to enable the Joint Force to operate effectively in CBRN-contested environments. Intellectual property considerations, teaming arrangements, and the scalability of therapeutic candidates are central to selection, with no socioeconomic or size status certifications required. The structure prioritizes agility, collaboration, and cross-sector innovation over rigid compliance, enabling a dynamic pipeline of medical countermeasures capable of addressing evolving biological threats through sustained host resilience.
W6QK Acc-Apg

POSTED

4 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Non-Optical Methods for High Speed Protein ControlDARPA’s Biological Technologies Office is seeking innovative solutions through the ERIS Marketplace to develop a new class of rapidly switchable, non-optogenetic protein domains capable of enabling real-time, massless control of cellular processes. The goal is to create a robust, modular molecular tool that responds to non-optical external signals such as magnetic fields or focused ultrasound, allowing precise regulation of protein function across cell membranes without relying on light or chemicals. Proposed solutions must achieve activation and deactivation kinetics of no more than two seconds, demonstrate reliable performance through at least 300 repetitive cycles in living cells, and function effectively in both split-protein dimerization and allosteric conformational configurations. This effort explicitly excludes any modifications or enhancements to existing optogenetic, light-based, or chemical systems. The anticipated contract value is $400,000 for a 12-month performance period, with awards being made on a rolling basis as solutions are evaluated, and the government reserves the right to issue awards before the December 8, 2026 submission deadline. Proposals must be submitted via the DARPA Connect ERIS Portal as a video that follows the required title format, or existing awardable solutions may be flagged for consideration by emailing ERIS@darpa.mil with specific subject and body requirements. Evaluation will focus on four core areas: a deep understanding of the problem space and current limitations in fields like sonogenetics and magnetogenetics, a significant technical leap in achieving rapid and repeatable protein control, demonstrated expertise in synthetic biology, protein engineering, and biophysics with a proven track record of quantitative in vivo characterization, and the potential of the solution to become a foundational tool in synthetic biology with broad applications in defense-relevant areas such as biomanufacturing, cell-based therapeutics, and biosensing. All submissions are subject to the ERIS assessment process, which serves as a mandatory pass/fail gate—only solutions deemed awardable by this process will be considered for BTO award. The procuring agency is the Department of Defense through DARPA’s Arlington, VA office, and all participants must comply with the ERIS Master Solicitation requirements available via SAM.gov.
Defense Advanced Research Projects Agcy

POSTED

4 days ago

DEADLINE

in 5 months
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao

Same awarding agency

NAICS: 541611
New
Federal
Intellectual Property Transfer and MTA Compliance SupportThe contract encompasses the legal and technical transfer of intellectual property associated with the transferrin receptor under a Materials Transfer Agreement, requiring comprehensive documentation and secure packaging of all relevant data to ensure full compliance with National Institutes of Health intellectual property policies. The work must be executed with precision to meet federal standards for IP handoff, including chain-of-custody records, data integrity protocols, and adherence to NIH-specific regulatory frameworks governing the movement of biological materials and associated proprietary information. The performance location is designated as Bethesda, Maryland, with a strict response deadline of July 31, 2026, and the opportunity is classified as a subcontract under NAICS code 541611, reflecting its alignment with scientific research and development services. The contracting entity is the National Institutes of Health, operating through the Department of Health and Human Services, and all activities must be coordinated to satisfy federal compliance requirements without deviation. Although no specific point of contact is provided, the submission must demonstrate proven expertise in IP transfer procedures, materials handling, and NIH policy alignment to qualify for award.
Administrative Management and General Management Consulting Services

POSTED

about 19 hours ago

DEADLINE

in 6 days
View Details
NAICS: 484220
New
Federal
Specialized Shipping & Delivery of Sensitive Laboratory EquipmentThe contract entails the specialized transportation and secure delivery of a GentleMACS instrument from the vendor to the National Institutes of Health’s Clinical Pharmacology Laboratory located in Bethesda, Maryland, with a strict requirement to prevent any physical damage during transit. The shipment must be handled by personnel experienced in moving sensitive laboratory equipment, utilizing appropriate packaging, climate-controlled and vibration-damped transport methods, and following established protocols to ensure the integrity of the device. Full documentation is required throughout the process, including pre-shipment inspections, real-time tracking records, condition reports upon arrival, and signed acceptance acknowledgments from the receiving facility. This subcontract falls under the NAICS code 484220 for specialized freight trucking and is issued under the Department of Health and Human Services through the National Institutes of Health. The place of performance is clearly defined as Bethesda, Maryland, with a ZIP code of 20892, and the work must be completed in alignment with federal standards for handling delicate scientific instruments. The contract emphasizes precision, accountability, and compliance, making thorough logistical planning and risk mitigation essential to successful fulfillment. All parties involved must ensure that the delivery meets the rigorous standards expected in a federal research environment.
Specialized Freight (except Used Goods) Trucking, Local

POSTED

about 19 hours ago

DEADLINE

N/A
View Details